Amgen Inc. AMGN
At closeNov 4, 2026, 5:32 PM EST
After hours · Nov 4, 5:32 PM ET
- YTD
- +46.19%
- 1 year
- +61.27%
- Market cap
- 258.68B
- Revenue (ttm)
- 38.09B
- Profit margin
- 22.95%
- EPS (ttm)
- 16.10
- Shares out
- 540.63M
- P/E ratio
- 29.72
- Forward P/E
- 19.46
- Dividend
- 10.08 (2.19%)
- Ex-dividend date
- Nov 19, 2026
- YTD return
- +46.19%
- 1-year return
- +61.27%
- Volume
- 4.47M
- Avg volume
- 2.78M
- Open
- 479.61
- Previous close
- 461.26
- Day's range
- 464.13 – 482.48
- 52-week range
- 302.13 – 482.48
- Beta
- 0.42
- Analysts
- Hold
- Price target
- 404.32 (-15.5%)
- Earnings date
- Feb 2, 2027
YTD +150.84 (+46.04%)
Key statistics
- Enterprise value
- 292.69B
- PEG ratio
- 2.75
- Price / sales
- 6.79
- Price / book
- 29.78
- Dividend yield
- 2.19%
- Payout ratio
- 60.87%
- Revenue growth
- 9.50%
- Free cash flow
- 8.65B
- Total cash
- 13.99B
- Total debt
- 57.30B
- Return on equity
- 91.47%
- Short % of float
- 2.48%
- 50-day average
- 420.83
- 200-day average
- 376.12
Analyst view
Consensus: hold
- Target (low)
- 225.00
- Target (mean)
- 404.32
- Target (high)
- 536.00
- Strong buy4
- Buy8
- Hold17
- Sell3
- Strong sell2
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 5.76.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | 5.79 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | 5.79 | 6.45 | +0.66 | +11.40% |
| Aug 4, 2026 | Jun 30, 2026 | 5.62 | 6.29 | +0.67 | +11.92% |
| Apr 30, 2026 | Mar 31, 2026 | 4.77 | 5.15 | +0.38 | +7.97% |
| Feb 3, 2026 | Dec 31, 2025 | 4.73 | 5.29 | +0.56 | +11.84% |
| Nov 4, 2025 | Sep 30, 2025 | 5.02 | 5.64 | +0.62 | +12.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | JP Morgan | main | Neutral | Neutral |
| Nov 4, 2026 | TD Cowen | main | Buy | Buy |
| Nov 4, 2026 | Goldman Sachs | main | Buy | Buy |
| Nov 4, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Nov 4, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 4, 2026 | Truist Securities | main | Hold | Hold |
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- amgen.com
News
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $530 
Citigroup Maintains Neutral on Amgen, Raises Price Target to $465 
JP Morgan Maintains Neutral on Amgen, Raises Price Target to $425 
TD Cowen Maintains Buy on Amgen, Raises Price Target to $531 
Goldman Sachs Maintains Buy on Amgen, Raises Price Target to $536 
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data 
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data 
Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $410 - RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470
AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook
Your note
Sign in to keep a note on AMGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADNER JAMES E. | Officer | Stock Award(Grant) | May 4, 2026 | 30,462 |
| BRADWAY ROBERT A | Chief Executive Officer | Stock Award(Grant) | May 4, 2026 | 657,299 |
| ECKERT ROBERT ANDREW | Director | Stock Award(Grant) | May 18, 2026 | 26,251 |
| GORDON MURDO | Officer | Stock Award(Grant) | May 4, 2026 | 51,837 |
| GRAHAM JONATHAN P | General Counsel | Stock Award(Grant) | May 4, 2026 | 40,211 |
| GRIFFITH PETER H. | Chief Financial Officer | Stock Award(Grant) | May 4, 2026 | 50,706 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.13% | 49,362,016 | 23.62B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.52% | 35,250,101 | 16.87B | Jun 29, 2026 |
| State Street Corporation | 5.65% | 30,560,537 | 14.62B | Jun 29, 2026 |
| Capital World Investors | 5.38% | 29,075,329 | 13.91B | Jun 29, 2026 |
| Invesco Ltd. | 3.02% | 16,320,446 | 7.81B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.90% | 15,696,068 | 7.51B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 17,134,234 | 8.20B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 13,987,160 | 6.69B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.27% | 12,272,320 | 5.87B | Aug 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 11,292,468 | 5.40B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 7,201,561 | 3.45B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 7,026,036 | 3.36B | Sep 29, 2026 |